Skip to main content

Lee McCracken

Molecular Diagnostics has appointed Lee McCracken to its board of directors. In 2014, McCracken was appointed CEO of Gensignia Life Sciences. Previously, he held positons as president and CEO of Pathwork Diagnostics. Before that, McCracken served as corporate head of business development at Prometheus Laboratories, senior vice president of pharma business development at Diversa (merged with Verenium), president and chief business officer of GenStar Therapeutics, and senior vice president of corporate development at CombiChem (acquired by DuPont Pharmaceuticals). 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.